Determinación de sulfato de bario, óxidos de titanio y partículas de carbono en la capa superficial de los monumentos históricos-artísticos

La caracterización cualitativa y cuantitativa de determinadas fases presentes en la superficie de los materiales ornamentales presenta grandes dificultades por encontrarse en muy baja proporción, además de otras dificultades analíticas. En este trabajo se describe un método para aislar el sulfato de bario y los óxidos de titanio presentes en capas superficiales de edificios localizados en áreas conta minadas. Previa extracción de compuestos orgánicos e iones solubles, se procede a un ataque ácido empleando una mezcla de HF, HNOy y HCIO4. El residuo ais lado por este método se caracterizó mediante microscopía electrónica de bamdo, análisis químico por dispersión de energías de rayos X y difracción de rayos X. Estimándose los porcentajes de carbono, barita (sulfato de bario), anatasa (óxido de titanio) y rutilo (óxido de titanio) presentes en las capas superficiales

Virological and immunological outcome of treatment interruption in HIV-1-infected subjects vaccinated with MVA-B

The most relevant endpoint in therapeutic HIV vaccination is the assessment of time to viral rebound or duration of sustained control of low-level viremia upon cART treatment cessation. Structured treatment interruptions (STI) are however not without risk to the patient and reliable predictors of viral rebound/control after therapeutic HIV-1 vaccination are urgently needed to ensure patient safety and guide therapeutic vaccine development. Here, we integrated immunological and virological parameters together with viral rebound dynamics after STI in a phase I therapeutic vaccine trial of a polyvalent MVA-B vaccine candidate to define predictors of viral control. Clinical parameters, proviral DNA, host HLA genetics and measures of humoral and cellular immunity were evaluated. A sieve effect analysis was conducted comparing pre-treatment viral sequences to breakthrough viruses after STI. Our results show that a reduced proviral HIV-1 DNA at study entry was independently associated with two virological parameters, delayed HIV-1 RNA rebound (p = 0.029) and lower peak viremia after treatment cessation (p = 0.019). Reduced peak viremia was also positively correlated with a decreased number of HLA class I allele associated polymorphisms in Gag sequences in the rebounding virus population (p = 0.012). Our findings suggest that proviral DNA levels and the number of HLA-associated Gag polymorphisms may have an impact on the clinical outcome of STI. Incorporation of these parameters in future therapeutic vaccine trials may guide refined immunogen design and help conduct safer STI approaches

Relaciones humanas, comunicación y normativa durante la pandemia

A principios del año 2020, la humanidad se enfrentó a una problemática de salud pública sin precedentes en la historia, la cual, a pesar de sus obstáculos, también puso sobre la mesa nuevos retos en todas las dimensiones del ser humano, no solo en lo concerniente a la salud. Por esta razón, la Universidad Sergio Arboleda, a través de la iniciativa Autores 4.0 de la Dirección de Publicaciones Científicas y el proyecto Show & Write y con un aporte multi-campus de sus Escuelas, se propuso analizar la realidad que ha traído el covid-19 desde una perspectiva interdisciplinar para así poder proponer diferentes soluciones a estas nuevas dificultades. Con diferentes metodologías cualitativas y cuantitativas, el presente libro de investigación se divide en dos secciones: la primera está enfocada en los cambios que han sufrido las relaciones humanas y los diferentes medios de comunicación, y propone soluciones creativas a las limitaciones impuestas por la pandemia. Y la segunda sección está enfocada en analizar los cambios que han surgido, principalmente, en el mercado laboral y en los pueblos indígenas, a raíz de las nuevas exigencias en el orden legal

Espectro clínico de la Enfermedad de Castleman

RESUMEN La enfermedad de Castleman(EC) es una enfermedad hematológica rara caracterizada por hiperplasia de nódulos linfoides con dos patrones histológicos y clínicos bien diferenciados: hialino-vascular que suele ser unicéntrico, de comportamiento poco agresivo y cuya exeresis consigue la curación en la mayor parte de los casos. La variante plasmocelular es más agresiva, su presentación clínica remeda los linfomas de alto grado y requiere quimioterapia para su erradicación. Juegan un papel etiopatogenico el HVH-8 y las interleucinas IL-6 e IL-1. Nuevos fármacos basados en el bloqueo de la IL-6 o su receptor han demostrado recientemente su utilidad para el control de la enfermedad. Presentamos cuatro casos clínicos que representan el espectro de la EC. ABSTRACT Castleman 's disease (CD) is a rare hematological disease characterized by hyperplasia of lymphoid nodules with two distinct histological and clinical patterns : hyaline - vascular which is usually single-center , low and aggressive behavior which gets exeresis healing in most of cases . The plasma cell variant is more aggressive clinical presentation mimics high-grade lymphomas and requires chemotherapy to eradicate. Play an etiopathogenic role HHV -8 and IL -6 and IL -1 cytokines. New drugs based on the blockade of IL -6 or its receptors have recently proved useful in the control of the disease. We present four cases representing the spectrum of CD

Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets

Current research on antiretroviral therapy is mainly focused in the development of new formulations or combinations of drugs belonging to already known targets. However, HIV-1 infection is not cured by current therapy and thus, new approaches are needed. Bevirimat was developed by chemical modification of betulinic acid, a lupane-type pentacyclic triterpenoid (LPT), as a first-in-class HIV-1 maturation inhibitor. However, in clinical trials, bevirimat showed less activity than expected because of the presence of a natural mutation in Gag protein that conferred resistance to a high proportion of HIV-1 strains. In this work, three HIV-1 inhibitors selected from a set of previously screened LPTs were investigated for their targets in the HIV-1 replication cycle, including their maturation inhibitor effect. LPTs were found to inhibit HIV-1 infection acting as promiscuous compounds with several targets in the HIV-1 replication cycle. LPT12 inhibited HIV-1 infection mainly through reverse transcription, integration, viral transcription, viral proteins (Gag) production and maturation inhibition. LPT38 did it through integration, viral transcription or Gag production inhibition and finally, LPT42 inhibited reverse transcription, viral transcription or Gag production. The three LPTs inhibited HIV-1 infection of human primary lymphocytes and infections with protease inhibitors and bevirimat resistant HIV-1 variants with similar values of IC50. Therefore, we show that the LPTs tested inhibited HIV-1 infection through acting on different targets depending on their chemical structure and the activities of the different LPTs vary with slight structural alterations. For example, of the three LPTs under study, we found that only LPT12 inhibited infectivity of newly-formed viral particles, suggesting a direct action on the maturation process. Thus, the multi-target behavior gives a potential advantage to these compounds since HIV-1 resistance can be overcome by modulating more than one target

New chronological constraints on intense Holocene eruptions and landslide activity at Tacaná volcanic complex (Mexico)

International audienc

Table1_Promiscuous, Multi-Target Lupane-Type Triterpenoids Inhibits Wild Type and Drug Resistant HIV-1 Replication Through the Interference With Several Targets.docx

<p>Current research on antiretroviral therapy is mainly focused in the development of new formulations or combinations of drugs belonging to already known targets. However, HIV-1 infection is not cured by current therapy and thus, new approaches are needed. Bevirimat was developed by chemical modification of betulinic acid, a lupane-type pentacyclic triterpenoid (LPT), as a first-in-class HIV-1 maturation inhibitor. However, in clinical trials, bevirimat showed less activity than expected because of the presence of a natural mutation in Gag protein that conferred resistance to a high proportion of HIV-1 strains. In this work, three HIV-1 inhibitors selected from a set of previously screened LPTs were investigated for their targets in the HIV-1 replication cycle, including their maturation inhibitor effect. LPTs were found to inhibit HIV-1 infection acting as promiscuous compounds with several targets in the HIV-1 replication cycle. LPT12 inhibited HIV-1 infection mainly through reverse transcription, integration, viral transcription, viral proteins (Gag) production and maturation inhibition. LPT38 did it through integration, viral transcription or Gag production inhibition and finally, LPT42 inhibited reverse transcription, viral transcription or Gag production. The three LPTs inhibited HIV-1 infection of human primary lymphocytes and infections with protease inhibitors and bevirimat resistant HIV-1 variants with similar values of IC₅₀. Therefore, we show that the LPTs tested inhibited HIV-1 infection through acting on different targets depending on their chemical structure and the activities of the different LPTs vary with slight structural alterations. For example, of the three LPTs under study, we found that only LPT12 inhibited infectivity of newly-formed viral particles, suggesting a direct action on the maturation process. Thus, the multi-target behavior gives a potential advantage to these compounds since HIV-1 resistance can be overcome by modulating more than one target.</p

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test.

The excessive use of piperacillin/tazobactam (P/T) has promoted the emergence of P/T-resistant Enterobacterales. We reported that in Escherichia coli, P/T contributes to the development of extended-spectrum resistance to β-lactam/β-lactamase inhibitor (BL/BLI) (ESRI) in isolates that are P/T susceptible but have low-level resistance to BL/BLI. Currently, the detection of P/T resistance relying on conventional methods is time-consuming. To overcome this issue, we developed a cost-effective test based on MALDI-MS technology, called MALDIpiptaz, which aims to detect P/T resistance and ESRI developers in E. coli. We used automated Clover MS Data Analysis software to analyse the protein profile spectra obtained by MALDI-MS from a collection of 248 E. coli isolates (91 P/T-resistant, 81 ESRI developers and 76 P/T-susceptible). This software allowed to preprocess all the spectra to build different peak matrices that were analysed by machine learning algorithms. We demonstrated that MALDIpiptaz can efficiently and rapidly (15 min) discriminate between P/T-resistant, ESRI developer and P/T-susceptible isolates and allowed the correct classification between ESRI developers from their isogenic resistance to P/T. The combination of excellent performance and cost-effectiveness are all desirable attributes, allowing the MALDIpiptaz test to be a useful tool for the rapid determination of P/T resistance in clinically relevant E. coli isolates

Clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in patients with ulcerative colitis treated with two consecutive anti-TNF agents: data from the ENEIDA registry

Background: Infliximab seems to be the most efficacious of the three available anti-TNF agents for ulcerative colitis (UC) but little is known when it is used as the second anti-TNF. Objectives: To compare the clinical and treatment outcomes of a second subcutaneous or intravenous anti-TNF in UC patients. Design: Retrospective observational study. Methods: Patients from the ENEIDA registry treated consecutively with infliximab and a subcutaneous anti-TNF (or vice versa), naïve to other biological agents, were identified and grouped according to the administration route of the first anti-TNF into IVi (intravenous initially) or SCi (subcutaneous initially). Results: Overall, 473 UC patients were included (330 IVi and 143 SCi). Clinical response at week 14 was 42.7% and 48.3% in the IVi and SCi groups (non-statistically significant), respectively. Clinical remission rates at week 52 were 32.8% and 31.4% in the IVi and SCi groups (nonsignificant differences), respectively. A propensity-matched score analysis showed a higher clinical response rate at week 14 in the SCi group and higher treatment persistence in the IVi group. Regarding long-term outcomes, dose escalation and discontinuation due to the primary failure of the first anti-TNF and more severe disease activity at the beginning of the second anti-TNF were inversely associated with clinical remission. Conclusion: The use of a second anti-TNF for UC seems to be reasonable in terms of efficacy, although it is particularly reduced in the case of the primary failure of the first anti-TNF. Whether the second anti-TNF is infliximab or subcutaneous does not seem to affect efficacy